Reuters logo
BRIEF-OPKO provides update to late-stage study of HGH-CTP in growth hormone deficient adults
June 15, 2017 / 1:41 PM / 6 months ago

BRIEF-OPKO provides update to late-stage study of HGH-CTP in growth hormone deficient adults

June 15 (Reuters) - OPKO Health Inc-

* OPKO provides update to topline data of phase 3 clinical study of hgh-ctp in growth hormone deficient adults

* OPKO Health - completed post-hoc sensitivity analyses to evaluate influence of outliers on primary endpoint results using multiple statistical approaches

* OPKO Health Inc - additional analyses that did not exclude outliers showed mixed results

* OPKO Health - analyses that excluded outliers showed a statistically significant difference between hgh-ctp and placebo on change in trunk fat mass

* OPKO Health Inc - preparation for pivotal pediatric ghd trial in japan is progressing and site selection is near completion

* OPKO Health - plans to utilize multi-dose pen for patients who continue in open label extension phase of adult phase 3, pediatric phase 2 ghd studies Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below